INTRODUCTION
Ocular inflammation, if left untreated, can lead to temporary or permanent vision loss.
Corticosteroids have been a mainstay in treating a variety of ocular diseases and conditions that have an inflammatory component due to their ability to elicit broad anti-inflammatory effects. Loteprednol etabonate, a corticosteroid that was developed for ophthalmic use, was designed using the soft drug concept in an effort to retain the therapeutic corticosteroid activity while minimizing adverse side effects [1, 2] .
Loteprednol etabonate has been available for ophthalmic use in a variety of formulations for the past 15 years. Clinical studies evaluating the safety and efficacy of loteprednol etabonate have been performed for a number of ophthalmic conditions, including dry eye [3] , seasonal allergic conjunctivitis [4] , anterior uveitis [5] , giant papillary conjunctivitis [6, 7] , and treatment of pain and inflammation following cataract surgery [8] [9] [10] . Additionally, studies with various steroids assessing the risk of intraocular pressure (IOP) elevation, a common concern associated with ocular steroids, indicate that there may be reduced risk for loteprednol etabonate, as compared to other corticosteroids [11] [12] [13] .
Topical application of therapeutic agents provides direct access to the target tissue; however, the ocular surface provides a set of unique challenges for topical penetration.
Mechanisms to eliminate foreign material from the ocular surface include blinking, tear flow, and drainage through the nasolacrimal duct. Moreover, cornea and conjunctiva are naturally covered with a 3-to 40-lm layer of mucus [14] [15] [16] . The outer layer is comprised of secreted and other mucins (cleared rapidly by mucin turnover and blinking), whose primary role is to trap and eliminate allergens, pathogens and debris (including therapeutic particles) from the eye [17] . The inner layer (up to 500-nm thick) is formed by epitheliumtethered mucins (glycocalyx), which protect the corneal tissue from abrasive stress and are cleared less rapidly [17] . Drug carriers that can penetrate the rapidly cleared outer mucous layer and reach the slow-clearing glycocalyx are likely to reside at the ocular surface longer and facilitate drug release directly to the underlying tissue. However, conventional attempts to improve retention of agents on ocular surface often focus on designing ophthalmic formulations with higher viscosity, such as ointments or gels, which may have tolerability issues [18] .
In an effort to circumvent the barrier presented by the mucous layers, novel formulations have been developed using a proprietary method to create mucuspenetrating nanoparticles [19] . This drug delivery platform allows for diffusion through the mucus and facilitates an even distribution of the nanoparticles across the ocular surface.
The overall goal of the loteprednol etabonate mucus-penetrating particles suspension formulation, 0.4% (LE-MPP 0.4%) is to improve drug penetration into tissues underlying the mucous barrier.
A previous report based on 14 into the cornea, with reduced penetration into the aqueous humor and iris/ciliary body [20] . In this study, we investigate the effect of using a novel MPP formulation on the pharmacokinetic profile of loteprednol etabonate in the ocular tissues of rabbits. A novel ophthalmic formulation of LE-MPP was prepared using a proprietary technology as described elsewhere [21] . Briefly, to generate LE-MPP, a milling procedure was employed in which an aqueous dispersion containing coarse drug particles and an MPP-enabling surface-altering agent was milled with grinding Ocular irritation assessments were conducted according to the method reported by Draize et al. [22] , for all animals prior to dosing (pre-dose) and prior to the necropsy. All samples were assayed using liquid chromatography-tandem mass spectrometry (LC/MS/MS). The analysis for each matrix was performed separately, and tissue-specific standard curves were generated separately for both formulations. For animals treated with Lotemax 0.5%, the analytical method had a lower limit of quantification (LLOQ) of 0.02 ng/ mL for plasma, 0.01 ng/mL for aqueous humor, 0.1 ng/g for cornea and iris/ciliary body, 2.0 ng/ g for conjunctiva, and 0.4 ng/g for retina. For animals treated with LE-MPP 0.4%, the LLOQ was 0.02 ng/mL for plasma, 0.01 ng/mL for aqueous humor, 0.1 ng/g for cornea, 0.2 ng/g for conjunctiva and iris/ciliary body, and 0.4 ng/g for retina. Plasma and aqueous humor samples were diluted with control plasma or aqueous humor, respectively, and analyzed directly. Ocular tissue samples were weighed, homogenized, and diluted with methanol prior to analysis.
MATERIALS AND METHODS

Statistical Analysis
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RESULTS
Samples from all 48 rabbits (96 eyes) were included in the analysis for this study. Rabbits in all groups had normal appearing ocular tissues pre-dose and prior to necropsy. No abnormal scores were observed per the Draize method of scoring [22] .
Concentrations of loteprednol etabonate in the aqueous humor are shown in Fig. 1 . For Fig. 2 . The drug absorbed rapidly into the tissues from both formulations, with the highest levels observed at the earliest time point of 0.083 h (5 min), then declining towards the LLOQ after the first 3 h. Nevertheless, the peak levels in the cornea and conjunctiva were 3.6-and 2.6-fold higher, respectively, for LE-MPP 0.4% than those for Lotemax 0.5%. The AUC 0-12 h, was 1.5-fold higher in the cornea for LE-MPP 0.4% than that of Lotemax 0.5%.
Concentrations of loteprednol etabonate in the iris/ciliary body and retina are shown in (Fig. 3a) . T max in the retina (Fig. 3b) 
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